BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 ... MarketWatch (press release) Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. BL-8040 was licensed by BioLineRx from ... |